Predict your next investment

Corporate Venture
nanfunglifesciences.com

See what CB Insights has to offer

Investments

18

Portfolio Exits

1

Partners & Customers

1

About Nan Fung Life Sciences

Nan Fung Life Sciences life sciences investment platform with a long-term capital commitment from the Nan Fung Group.

Nan Fung Life Sciences Headquarter Location

San Francisco, California, 94107,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Nan Fung Life Sciences News

Ablaze Pharmaceuticals Launches with $75m Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market

Nov 29, 2021

Intellasia East Asia News 29-Nov-2021 Intellasia | PR Newswire Asia | 9:00 AM SHANGHAI and SAN DIEGO, Nov. 29, 2021 /PRNewswire/ -- Ablaze Pharmaceuticals ("Ablaze"), a clinical-stage pharmaceutical company focused on the development and commercialization of innovative targeted radiopharmaceutical therapies (TRT) against tumor targets, announced a $75 million Series A financing round. The financing was co-led by Vivo Capital and AdvanTech Capital with participation from RAYZ Investments, Nan Fung Life Sciences, Pivotal bioVenture Partners China, venBio Partners, Samsara BioCapital and Venrock Healthcare Capital Partners. "Targeted radiopharmaceutical therapies represent the next foundational modality to treat cancer," said Dr. Ken Song, co-founder and Chairman of the Board of Ablaze and President and CEO of RayzeBio, Inc. "In forming Ablaze, we realized to be successful, it was critical to have a company focused on the China market and focused on radiopharmaceuticals." With TRT gaining broader interest and adoption, Ablaze was formed to become the leading radiopharmaceutical company to introduce TRT products to the Greater China market. Led by an experienced team and a strong investor syndicate, Ablaze started on a solid footing, anchoring with a strategic RayzeBio in-licensing agreement, and a partnership with an academic institution on a clinical stage asset. Upon closure of the Series A, Ablaze is also actively exploring other potential partnerships, and building strong internal development capabilities. "TRT is an emerging field that has already demonstrated tremendous clinical efficacy in treating cancer worldwide. We are privileged to have an opportunity to partner with Ablaze and the RayzeBio team in developing this category of potentially life-saving therapeutics for cancer patients in China." said Dr. Hongbo Lu, Managing Partner of Vivo Capital. Proceeds from the Series A financing will be used by Ablaze to establish a leading pipeline of advanced TRT products for the treatment of solid tumors, expand the leadership team, build up infrastructure for radiopharmaceuticals and secure further strategic collaborations. The board of directors include Dr. Alex Qiao, co-founder and President and CEO of Ablaze Pharmaceuticals, Dr. Hongbo Lu, Benjamin Qiu, Partner at AdvanTech Capital, Dr. Aaron Royston, Managing Partner at venBio Partners, and Dr. Ken Song as well as Norman Tse, Vice President at Nan Fung Life Sciences as board observer. "We believe Ablaze is bringing world class design of TRT products as well as clinical expertise to China through collaborations with global leaders in TRT, and is determined to be a leading player in China's TRT innovations" said Mr. Benjamin Qiu. "We are excited about this opportunity to bring a novel class of therapeutic products to benefit patients in China," said Dr. Alex Qiao. "This investment from top tier investors in China and abroad provides a strong endorsement to Ablaze's vision and business model. We look forward to creating the best and differentiated medicines to address unmet medical needs in China." About Ablaze Pharmaceuticals Founded in 2021, Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company with a mission to bring advanced targeted radiopharmaceutical therapies (TRT) to benefit cancer patients in China. Since its inception, Ablaze has secured a partnership with RayzeBio, Inc., an innovative radiopharmaceutical company based in San Diego CA, to gain exclusive development and commercial right to a series of RayzeBio's products in the greater China region. Leveraging its team's extensive business experience and network in cross-border product development and deal making, Ablaze strives to become the leader and the partner of choice in the emerging TRT market in China by working with strategic business partners in both China and abroad. For more information, please visit www.ablazepharma.com About Vivo Capital Founded in 1996, Vivo Capital is a global investment firm focused on healthcare. Vivo has approximately $5.8 billion in assets under management, invested in over 310 public and private companies worldwide. The firm is headquartered in Palo Alto, California, with additional offices in Asia. The Vivo team consists of more than 50 multi-disciplinary professionals, including, physicians, scientists, entrepreneurs, operating executives, and industry experts. Vivo provides a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets. About AdvanTech Capital Launched in January 2016, AdvanTech Capital is a private equity fund, focused on innovation-driven growth capital in China. AdvanTech, focuses on healthcare and TMT / e-Services sectors, is managed by over a dozen seasoned investment professionals with local and overseas educational background, as well as diversified and in-depth local knowledge, practical deal execution capabilities and experiences. About Nan Fung Life Sciences & Pivotal bioVenture Partners China Nan Fung Life Sciences is a global life sciences investment platform with a long-term capital commitment from the Nan Fung Group. The team possesses diverse experience with long track records in company formation, venture capital, growth/buyout investments, and drug discovery and development. For more information, please visit https://www.nanfunglifesciences.com Pivotal bioVenture Partners China, a member of Nan Fung Life Sciences, is a venture capital firm specializing in the healthcare and life sciences industry. Its investment strategy is centered on identifying promising innovative products and technologies and bringing them to build out new companies in China. For more information, please visit https://www.pivotalbiovp.cn

Nan Fung Life Sciences Investments

18 Investments

Nan Fung Life Sciences has made 18 investments. Their latest investment was in Ablaze Pharmaceuticals as part of their Series A on November 11, 2021.

CBI Logo

Nan Fung Life Sciences Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/29/2021

Series A

Ablaze Pharmaceuticals

$75M

Yes

7

11/18/2021

Series A - III

Fountain Therapeutics

$15M

No

5

8/3/2021

Series A - II

Engrail Therapeutics

$32M

No

7

5/5/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

3/10/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/29/2021

11/18/2021

8/3/2021

5/5/2021

3/10/2021

Round

Series A

Series A - III

Series A - II

Series C

Series B

Company

Ablaze Pharmaceuticals

Fountain Therapeutics

Engrail Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$75M

$15M

$32M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

7

5

7

10

10

Nan Fung Life Sciences Portfolio Exits

1 Portfolio Exit

Nan Fung Life Sciences has 1 portfolio exit. Their latest portfolio exit was Eargo on October 16, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/16/2020

IPO

$99M

2

Date

10/16/2020

Exit

IPO

Companies

Valuation

$99M

Acquirer

Sources

2

Nan Fung Life Sciences Partners & Customers

1 Partners and customers

Nan Fung Life Sciences has 1 strategic partners and customers. Nan Fung Life Sciences recently partnered with Celltrion on July 7, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

7/22/2019

Partner

Celltrion

South Korea

Celltrion and Nan Fung Group to establish Vcell Healthcare Limited to Develop and Commercialize Biosimilars in China – Nan Fung Life Sciences

Leveraging on Nan Fung Group 's strong capital base and long term commitment to the area , Nan Fung Life Sciences aims to become the ideal partner for scientists , entrepreneurs , corporations and investors in the life science space .

1

Date

7/22/2019

Type

Partner

Business Partner

Celltrion

Country

South Korea

News Snippet

Celltrion and Nan Fung Group to establish Vcell Healthcare Limited to Develop and Commercialize Biosimilars in China – Nan Fung Life Sciences

Leveraging on Nan Fung Group 's strong capital base and long term commitment to the area , Nan Fung Life Sciences aims to become the ideal partner for scientists , entrepreneurs , corporations and investors in the life science space .

Sources

1

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.